

NIHR

Routinely used interventions to improve attachment in infants and young children: a national survey and two systematic reviews

This study found the most commonly used attachment interventions in UK services currently have a limited evidence base and those with stronger evidence bases are less widely used. There is a need for better links between research and practice to ensure that interventions offered to families are safe and effective. Possible reasons for the disparity include the cost and accessibility of training. There is also a need for improved understanding by professionals regarding the meaning of attachment.

Systematic search: Yes

February 2023

<https://www.journalslibrary.nihr.ac.uk/hta/IVCN8847/#/abstract>

The King's Fund

Nil

Scottish Medicines Consortium (SMC Advice)

pembrolizumab (Keytruda®)

Accepted for restricted use in combination with chemotherapy, with or without bevacizumab, for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express programmed death ligand 1 (PD-L1) with a combined positive score (CPS)≥1. Treatment with pembrolizumab is subject to a two-year clinical stopping rule.

Systematic search: No

February 2023

<https://www.scottishmedicines.org.uk/medicines-advice/pembrolizumab-keytruda-cc-full-smc2501/>

nivolumab (Opdivo®)

Accepted for use as monotherapy for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (MIUC) with tumour cell PD-L1 expression ≥1%, who are at high risk of recurrence after undergoing radical resection of MIUC.

Systematic search: No

February 2023

<https://www.scottishmedicines.org.uk/medicines-advice/nivolumab-opdivo-miuc-full-smc2503/>

burosumab (Crysvita)

Indication under review: Treatment of X-linked hypophosphataemia in adults. Scottish Government Medicines Policy Branch will notify Health Boards when this medicine is available for prescribing within the ultra-orphan pathway. Meantime any requests to access treatment should be considered through local non-formulary processes.

Systematic search: No

February 2023

<https://www.scottishmedicines.org.uk/medicines-advice/burosumab-crysvita-ultra-orphan-smc2514/>

upadacitinib (Rinvoq®)

Accepted for use for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP)

and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs)

Systematic search: No

February 2023

<https://www.scottishmedicines.org.uk/medicines-advice/upadacitinib-rinvoq-abb-smc2532/>

eptinezumab (Vyepti®)

Accepted for restricted use for the prophylaxis of migraine in adults who have at least 4 migraine days per month. Restricted to patients with chronic and episodic migraine who have had prior failure on three or more migraine preventive treatments.

Systematic search: No

February 2023

<https://www.scottishmedicines.org.uk/medicines-advice/eptinezumab-vyepti-abb-smc2547/>

Scottish Government

Mental health and wellbeing strategy: consultation analysis - executive summary

A new Mental Health and Wellbeing Strategy will be published in Spring 2023 and will be informed by the public consultation analysis. The consultation resulted in a considerable repetition of points throughout the consultation question responses. These included: a need for a stronger focus on prevention and early intervention; the importance of tackling poverty and inequality; supporting person-centred and whole-family approaches; placing mental health and wellbeing on an equal footing with physical health; a need for increased community-based support and services; increased and longer-term funding for mental health and wellbeing services, including for the third sector; growing the workforce – developing a skilled and diverse mental health and wellbeing workforce, and addressing talent attraction, recruitment, and retention challenges.

Systematic search: No

February 2023

<https://www.gov.scot/publications/analysis-public-consultation-new-mental-health-wellbeing-strategy-executive-summary/>

Improving equity of access to cancer clinical trials in Scotland

This report summarises the findings and recommendations of an Equity of Access Short Life Working Group. This is provided as a compilation of work package reports focusing on domains which impact on equity of access, including: opportunities and challenges for recovery of Scottish cancer research, cancer clinical trials data, cancer trials staffing and management, key performance indicators, financial models, use of digital technology, access to enhanced genomic testing and partnership working.

Systematic search: No

February 2023

<https://www.gov.scot/publications/improving-equity-access-cancer-clinical-trials-scotland/>

Supporting roots: report

Report providing a broad picture of the needs of birth parents who have lost a child or children to 'care', and of the support and services that are currently available in Scotland. This report is designed to support best practice and service innovation.

Systematic search: No

February 2023

<https://www.gov.scot/publications/supporting-roots/>

SIGN

Nil

Public Health Scotland

Ending violence against women and girls – a public health approach

This paper highlights the actions and conditions required to prevent violence against women and girls (VAWG). It explores the necessary steps to create a climate of prevention around VAWG issues and the opportunities to collaborate across sectors and with communities to create a fuller understanding of prevention approaches.

Systematic search: No

February 2023

<https://publichealthscotland.scot/publications/ending-violence-against-women-and-girls-a-public-health-approach>

NICE – Guidelines

NG231 Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and management

This guideline covers monitoring, treatment and follow-up for people aged 18 and over with Barrett's oesophagus and stage 1 oesophageal adenocarcinoma. It includes advice on endoscopic and non-endoscopic techniques. It aims to improve outcomes by ensuring the most effective investigations and treatments are used.

Systematic search: Limited

February 2023

<https://www.nice.org.uk/guidance/ng231>

NICE - Technology Appraisal Guidance

TA870 ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma

Systematic search: Limited

February 2023

<https://www.nice.org.uk/guidance/ta870>

TA868 Vutrisiran for treating hereditary transthyretin-related amyloidosis

Systematic search: Limited

February 2023

<https://www.nice.org.uk/guidance/ta868>

TA865 Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma

Systematic search: Limited

February 2023

<https://www.nice.org.uk/guidance/ta865>

TA866 Regorafenib for previously treated metastatic colorectal cancer

Systematic search: Limited

February 2023

<https://www.nice.org.uk/guidance/ta866>

TA861 Upadacitinib for treating active non-radiographic axial spondyloarthritis

Systematic search: Limited

February 2023

<https://www.nice.org.uk/guidance/ta861>

TA862 Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments

Systematic search: Limited

February 2023

<https://www.nice.org.uk/guidance/ta862>

TA864 Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted

Systematic search: Limited

February 2023

<https://www.nice.org.uk/guidance/ta864>

TA863 Somatrogen for treating growth disturbance in children and young people aged 3 years and over

Systematic search: Limited

February 2023

<https://www.nice.org.uk/guidance/ta863>

EPPI Centre

Nil

AHRQ (Agency for Healthcare Research and Quality – USA)

Nil

Health Foundation

Nil

Canadian Agency for drugs and Technologies in Health (CADTH)

Sotrovimab for the Treatment of COVID-19

Sotrovimab may not have clinical effectiveness in treating Omicron subvariant BA.2. This finding generally aligns with the Health Canada and WHO recommendations and the findings of previously published in vitro studies against the use of sotrovimab for Omicron subvariants, except for BA.1. Given the limited number and observational, nonrandomized design of the included studies, and the absence of evidence on the clinical effectiveness of sotrovimab for outpatients with confirmed COVID-19 Omicron subvariants BA.3 to BA.5, it is difficult to draw a firm conclusion about the clinical effectiveness of sotrovimab for Omicron subvariants.

Systematic search: Yes

February 2023

<https://www.cadth.ca/sotrovimab-treatment-covid-19>

Tenecteplase for Acute Ischemic Stroke

Two economic evaluation studies found that tenecteplase was the dominant treatment strategy (i.e., lower costs and higher benefit) compared with alteplase over a lifetime horizon.

Systematic search: Yes

February 2023

<https://www.cadth.ca/tenecteplase-acute-ischemic-stroke>

Wait List Strategies for CT and MRI

Identified principles for developing a plan to address wait times include engaging stakeholders, taking a coordinated approach to develop short- and long-term plans, ensuring plans are flexible to account for changes in technologies, and developing a plan for quality monitoring and assessment of specified outcomes. Identified strategies for reducing wait times for CT and/or MRI scans include increasing capacity, improving efficiencies, reducing low-value scans, improving communication, and adopting new technology.

Systematic search: Yes

January 2023

<https://www.cadth.ca/wait-list-strategies-ct-and-mri>

Copper and Ceruloplasmin Tests for Children With Global Developmental Delay and Intellectual Disability

No evidence was identified regarding the diagnostic test accuracy or clinical utility of copper and ceruloplasmin tests compared to other tests or criteria to detect Wilson disease and Menkes disease in children with global development delay and intellectual disability that met the criteria for this review. No evidence-based guidelines were found.

Systematic search: Yes

January 2023

<https://www.cadth.ca/copper-and-ceruloplasmin-tests-children-global-developmental-delay-and-intellectual-disability>

Community Supports for People with Tuberculosis

Some people with tuberculosis face barriers and may require assistance with care. For these populations, the use of support workers may be helpful for engaging patients and promoting treatment compliance. This report identifies and describes the strategies that support workers use to support tuberculosis treatment in people who require additional assistance with care.

Systematic search: Yes

January 2023

<https://www.cadth.ca/community-supports-people-tuberculosis>

McGill University Health Centre (Canada)

Nil

Health Information & Quality Authority (Ireland) – Health Technology Assessments

Nil

Campbell Collaboration

Non-familial intergenerational interventions and their impact on social and mental wellbeing of both younger and older people—a mapping review and evidence and gap map

The outcomes reported in the research cover mental health, physical health, attainment and knowledge, agency, mental wellbeing, loneliness and social isolation, attitudes towards the other generation, intergenerational interactions, peer interactions and health promotion and including mutual outcomes such as the impact on community and perceptions on the sense of community. Gaps in the evidence that were identified include: research that reports on mutual, societal and community outcomes of intergenerational interventions; more research on interventions classified as levels 1–4 and level 7 on the Intergenerational Engagement Scale, mental health, loneliness, social isolation, peer interactions, physical health and health promotion outcomes in children and young

people; health promotion in older people; outcomes centred on care giver wellbeing, mental health and attitudes; economic outcomes; process outcomes and adverse or unexpected outcomes.

Systematic search: Limited

January 2023

Glasgow Centre for Population Health

Changing mortality rates in Scotland and the UK: an updated summary

This paper provides further evidence of detrimental changes to different aspects of population health: further widening of all-cause and cause-specific mortality inequalities, a dramatic reversal of previously declining mortality rates among socioeconomically deprived populations, an unprecedented decline in healthy life expectancy, and worsening trends in poor mental health. The (much smaller) contribution of obesity to stalled national mortality trends is also quantified.

Systematic search: No

February 2023

https://www.gcph.co.uk/publications/1083_changing_mortality_rates_in_scotland_and_the_uk_an_updated_summary

Economies for Healthier Lives

This is a three-year (2021-24) programme managed and delivered by the Health Foundation. Funding has been allocated to four local partnerships across the UK to promote health and reduce inequalities through economic development strategies. The Glasgow Centre for Population Health is providing ongoing evaluation support to the Glasgow City Region (GCR) partnership, which includes annual reporting on progress and outcomes, beginning with this report at the end of year one.

Systematic search: No

February 2023

https://www.gcph.co.uk/assets/0000/9317/Economies_for_Healthier_Lives.pdf

NICE FORWARD PLANNING – Publications due MARCH 2023

Urinary tract infections in adults (update)

Quality Standard - update (new clinical practice evidence)

Diabetes in adults update - Type 1 and Type 2

Quality Standard - update (new clinical practice evidence)

Early Value Assessment: CaRi-Heart for predicting cardiac risk in suspected coronary artery disease

Diagnostic Technology - new

Head injury: assessment and early management

Clinical Guideline - update (new pharmaceutical and clinical practice evidence)

Early Value Assessment: ProKnow Cloud-based system for radiotherapy data archiving, communications and management

Medical Technology (new)

Acute kidney injury (update)

Quality Standard - update (new clinical practice evidence)

AposHealth for osteoarthritis (OA) of the knee

Medical Technology (new)